132 related articles for article (PubMed ID: 30595549)
1. Hif-1α Deletion May Lead to Adverse Treatment Effect in a Mouse Model of MLL-AF9-Driven AML.
Velasco-Hernandez T; Soneji S; Hidalgo I; Erlandsson E; Cammenga J; Bryder D
Stem Cell Reports; 2019 Jan; 12(1):112-121. PubMed ID: 30595549
[TBL] [Abstract][Full Text] [Related]
2. Hif-1α and Hif-2α synergize to suppress AML development but are dispensable for disease maintenance.
Vukovic M; Guitart AV; Sepulveda C; Villacreces A; O'Duibhir E; Panagopoulou TI; Ivens A; Menendez-Gonzalez J; Iglesias JM; Allen L; Glykofrydis F; Subramani C; Armesilla-Diaz A; Post AE; Schaak K; Gezer D; So CW; Holyoake TL; Wood A; O'Carroll D; Ratcliffe PJ; Kranc KR
J Exp Med; 2015 Dec; 212(13):2223-34. PubMed ID: 26642852
[TBL] [Abstract][Full Text] [Related]
3. Atg5-dependent autophagy contributes to the development of acute myeloid leukemia in an MLL-AF9-driven mouse model.
Liu Q; Chen L; Atkinson JM; Claxton DF; Wang HG
Cell Death Dis; 2016 Sep; 7(9):e2361. PubMed ID: 27607576
[TBL] [Abstract][Full Text] [Related]
4. The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia.
Baker A; Gregory GP; Verbrugge I; Kats L; Hilton JJ; Vidacs E; Lee EM; Lock RB; Zuber J; Shortt J; Johnstone RW
Cancer Res; 2016 Mar; 76(5):1158-69. PubMed ID: 26627013
[TBL] [Abstract][Full Text] [Related]
5. HIF-1α inhibition by 2-methoxyestradiol induces cell death via activation of the mitochondrial apoptotic pathway in acute myeloid leukemia.
Zhe N; Chen S; Zhou Z; Liu P; Lin X; Yu M; Cheng B; Zhang Y; Wang J
Cancer Biol Ther; 2016 Jun; 17(6):625-34. PubMed ID: 27082496
[TBL] [Abstract][Full Text] [Related]
6. Integrative single-cell expression and functional studies unravels a sensitization to cytarabine-based chemotherapy through HIF pathway inhibition in AML leukemia stem cells.
Velasco-Hernandez T; Trincado JL; Vinyoles M; Closa A; Martínez-Moreno A; Gutiérrez-Agüera F; Molina O; Rodríguez-Cortez VC; Ximeno-Parpal P; Fernández-Fuentes N; Petazzi P; Beneyto-Calabuig S; Velten L; Romecin P; Casquero R; Abollo-Jiménez F; de la Guardia RD; Lorden P; Bataller A; Lapillonne H; Stam RW; Vives S; Torrebadell M; Fuster JL; Bueno C; Sarry JE; Eyras E; Heyn H; Menéndez P
Hemasphere; 2024 Feb; 8(2):e45. PubMed ID: 38435427
[TBL] [Abstract][Full Text] [Related]
7. PBX3 is essential for leukemia stem cell maintenance in MLL-rearranged leukemia.
Guo H; Chu Y; Wang L; Chen X; Chen Y; Cheng H; Zhang L; Zhou Y; Yang FC; Cheng T; Xu M; Zhang X; Zhou J; Yuan W
Int J Cancer; 2017 Jul; 141(2):324-335. PubMed ID: 28411381
[TBL] [Abstract][Full Text] [Related]
8. Impact of loss of BH3-only proteins on the development and treatment of MLL-fusion gene-driven AML in mice.
Bilardi RA; Anstee NS; Glaser SP; Robati M; Vandenberg CJ; Cory S
Cell Death Dis; 2016 Sep; 7(9):e2351. PubMed ID: 27584789
[TBL] [Abstract][Full Text] [Related]
9. Murine Retrovirally-Transduced Bone Marrow Engraftment Models of MLL-Fusion-Driven Acute Myelogenous Leukemias (AML).
Stubbs MC; Krivtsov AV
Curr Protoc Pharmacol; 2017 Sep; 78():14.42.1-14.42.19. PubMed ID: 28892146
[TBL] [Abstract][Full Text] [Related]
10. Phosphoinositide-dependent kinase 1 regulates leukemia stem cell maintenance in MLL-AF9-induced murine acute myeloid leukemia.
Hu T; Li C; Zhang Y; Wang L; Peng L; Cheng H; Wang W; Chu Y; Xu M; Cheng T; Yuan W
Biochem Biophys Res Commun; 2015 Apr; 459(4):692-8. PubMed ID: 25769952
[TBL] [Abstract][Full Text] [Related]
11. MLL-AF9 Expression in Hematopoietic Stem Cells Drives a Highly Invasive AML Expressing EMT-Related Genes Linked to Poor Outcome.
Stavropoulou V; Kaspar S; Brault L; Sanders MA; Juge S; Morettini S; Tzankov A; Iacovino M; Lau IJ; Milne TA; Royo H; Kyba M; Valk PJM; Peters AHFM; Schwaller J
Cancer Cell; 2016 Jul; 30(1):43-58. PubMed ID: 27344946
[TBL] [Abstract][Full Text] [Related]
12. Structural maintenance of chromosomes 4 is required for leukemia stem cell maintenance in MLL-AF9 induced acute myeloid leukemia.
Peng L; Tang Y; Zhang Y; Guo S; Peng L; Ye L; Wang Y; Jiang Y
Leuk Lymphoma; 2018 Oct; 59(10):2423-2430. PubMed ID: 29043883
[TBL] [Abstract][Full Text] [Related]
13. Rheb1 promotes tumor progression through mTORC1 in MLL-AF9-initiated murine acute myeloid leukemia.
Gao Y; Gao J; Li M; Zheng Y; Wang Y; Zhang H; Wang W; Chu Y; Wang X; Xu M; Cheng T; Ju Z; Yuan W
J Hematol Oncol; 2016 Apr; 9():36. PubMed ID: 27071307
[TBL] [Abstract][Full Text] [Related]
14. Transient potential receptor melastatin-2 (Trpm2) does not influence murine MLL-AF9-driven AML leukemogenesis or in vitro response to chemotherapy.
Haladyna JN; Pastuer T; Riedel SS; Perraud AL; Bernt KM
Exp Hematol; 2016 Jul; 44(7):596-602.e3. PubMed ID: 27033163
[TBL] [Abstract][Full Text] [Related]
15. Genetic deletion or small-molecule inhibition of the arginine methyltransferase PRMT5 exhibit anti-tumoral activity in mouse models of MLL-rearranged AML.
Kaushik S; Liu F; Veazey KJ; Gao G; Das P; Neves LF; Lin K; Zhong Y; Lu Y; Giuliani V; Bedford MT; Nimer SD; Santos MA
Leukemia; 2018 Feb; 32(2):499-509. PubMed ID: 28663579
[TBL] [Abstract][Full Text] [Related]
16. HIF-1α can act as a tumor suppressor gene in murine acute myeloid leukemia.
Velasco-Hernandez T; Hyrenius-Wittsten A; Rehn M; Bryder D; Cammenga J
Blood; 2014 Dec; 124(24):3597-607. PubMed ID: 25267197
[TBL] [Abstract][Full Text] [Related]
17. Dual inhibition of EZH1/2 breaks the quiescence of leukemia stem cells in acute myeloid leukemia.
Fujita S; Honma D; Adachi N; Araki K; Takamatsu E; Katsumoto T; Yamagata K; Akashi K; Aoyama K; Iwama A; Kitabayashi I
Leukemia; 2018 Apr; 32(4):855-864. PubMed ID: 28951561
[TBL] [Abstract][Full Text] [Related]
18. CD93 Marks a Non-Quiescent Human Leukemia Stem Cell Population and Is Required for Development of MLL-Rearranged Acute Myeloid Leukemia.
Iwasaki M; Liedtke M; Gentles AJ; Cleary ML
Cell Stem Cell; 2015 Oct; 17(4):412-21. PubMed ID: 26387756
[TBL] [Abstract][Full Text] [Related]
19. Hypoxia inducible factor (HIF)-2α accelerates disease progression in mouse models of leukemia and lymphoma but is not a poor prognosis factor in human AML.
Forristal CE; Brown AL; Helwani FM; Winkler IG; Nowlan B; Barbier V; Powell RJ; Engler GA; Diakiw SM; Zannettino AC; Martin S; Pattabiraman D; D'Andrea RJ; Lewis ID; Levesque JP
Leukemia; 2015 Oct; 29(10):2075-85. PubMed ID: 25921247
[TBL] [Abstract][Full Text] [Related]
20. Id2 and E Proteins Orchestrate the Initiation and Maintenance of MLL-Rearranged Acute Myeloid Leukemia.
Ghisi M; Kats L; Masson F; Li J; Kratina T; Vidacs E; Gilan O; Doyle MA; Newbold A; Bolden JE; Fairfax KA; de Graaf CA; Firth M; Zuber J; Dickins RA; Corcoran LM; Dawson MA; Belz GT; Johnstone RW
Cancer Cell; 2016 Jul; 30(1):59-74. PubMed ID: 27374225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
